loading
Nuvectis Pharma Inc stock is traded at $5.10, with a volume of 169.98K. It is up +4.08% in the last 24 hours and down -36.80% over the past month. Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
See More
Previous Close:
$4.90
Open:
$4.94
24h Volume:
169.98K
Relative Volume:
0.97
Market Cap:
$91.19M
Revenue:
-
Net Income/Loss:
$-22.38M
P/E Ratio:
-3.2903
EPS:
-1.55
Net Cash Flow:
$-15.54M
1W Performance:
+3.03%
1M Performance:
-36.80%
6M Performance:
-23.54%
1Y Performance:
-37.65%
1-Day Range:
Value
$4.6106
$5.14
1-Week Range:
Value
$4.6106
$5.49
52-Week Range:
Value
$4.6106
$12.10

Nuvectis Pharma Inc Stock (NVCT) Company Profile

Name
Name
Nuvectis Pharma Inc
Name
Phone
360-837-7232
Name
Address
1 BRIDGE PLAZA, SUITE 275, FORT LEE
Name
Employee
13
Name
Twitter
Name
Next Earnings Date
2024-08-07
Name
Latest SEC Filings
Name
NVCT's Discussions on Twitter

Compare NVCT with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
NVCT 5.10 91.19M 0 -22.38M -15.54M -1.55
VRTX 450.97 116.38B 10.63B -479.80M -1.35B 13.33
REGN 738.00 82.09B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.14B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.25B 3.30B -501.07M 1.03B 11.54

Nuvectis Pharma Inc Stock (NVCT) Upgrades & Downgrades

Date Action Analyst Rating Change
Jul-13-22 Initiated Ladenburg Thalmann Buy

Nuvectis Pharma Inc Stock (NVCT) Latest News

pulisher
Nov 22, 2024

Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges - Investing.com Australia

Nov 22, 2024
pulisher
Nov 22, 2024

Nuvectis Pharma stock hits 52-week low at $4.7 amid market challenges By Investing.com - Investing.com South Africa

Nov 22, 2024
pulisher
Nov 21, 2024

Nuvectis sinks after early-stage data for ovarian cancer therapy - MSN

Nov 21, 2024
pulisher
Nov 21, 2024

Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock By Investing.com - Investing.com Australia

Nov 21, 2024
pulisher
Nov 21, 2024

Ron Bentsur Buys Handful Of Shares In Nuvectis Pharma - Simply Wall St

Nov 21, 2024
pulisher
Nov 21, 2024

Insider Buying: Nuvectis Pharma Inc (NVCT) Chairman & CEO Acquires Shares - GuruFocus.com

Nov 21, 2024
pulisher
Nov 20, 2024

Nuvectis pharma officer Enrique Poradosu buys $9,980 in stock - Investing.com

Nov 20, 2024
pulisher
Nov 19, 2024

Vitalli ends work on Daewoong asset; Alector’s $50M loan - Endpoints News

Nov 19, 2024
pulisher
Nov 18, 2024

Nuvectis Pharma, Inc. (NASDAQ:NVCT) CEO Ron Bentsur Buys 20,000 Shares - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

Nuvectis pharma chairman buys $98,400 in common stock By Investing.com - Investing.com Canada

Nov 18, 2024
pulisher
Nov 18, 2024

Nuvectis pharma chairman buys $98,400 in common stock - Investing.com

Nov 18, 2024
pulisher
Nov 15, 2024

Nuvectis Pharma reports data from Phase 1b study of NXP800 - Yahoo Finance

Nov 15, 2024
pulisher
Nov 14, 2024

Market Alert: Nuvectis Pharma reports promising data for NXP800 in Phase 1b; Advancing Towards Higher Dose Cohort - The Globe and Mail

Nov 14, 2024
pulisher
Nov 14, 2024

500: Something went wrong - Investing.com Canada

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug - Yahoo Finance

Nov 14, 2024
pulisher
Nov 14, 2024

NVCT stock touches 52-week low at $5.05 amid market fluctuations - Investing.com India

Nov 14, 2024
pulisher
Nov 14, 2024

U.S. Stock market: Nuvectis Pharma declined by 40.58% while Sow Good was down by 55.30% during mid day trading - Business Upturn

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis stock sinks on data for cancer drug (NVCT:NASDAQ) - Seeking Alpha

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis Pharma Stock Plummets on Updated Data for Ovarian Cancer Study - MarketWatch

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis Pharma Inc trading resumes - TipRanks

Nov 14, 2024
pulisher
Nov 14, 2024

U.S. Stock market: Nuvectis Pharma saw a sharp decline of 53.89% while AgEagle Aerial Systems surged by 133.74% in early trading - Business Upturn

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis Pharma Reports Encouraging NXP800 Interim Data - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase - The Bakersfield Californian

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis Pharma's NXP800 Shows Promise in Phase 1b Cancer Trial, New Dosing Success | NVCT Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Trading (NVCT) With Integrated Risk Controls - Stock Traders Daily

Nov 14, 2024
pulisher
Nov 14, 2024

Nuvectis Pharma (NASDAQ:NVCT) Announces Third Quarter 2024 Financial Results and Business Updates - Defense World

Nov 14, 2024
pulisher
Nov 13, 2024

Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why - Yahoo Finance

Nov 13, 2024
pulisher
Nov 11, 2024

Wall Street Analysts Predict a 169.94% Upside in Nuvectis Pharma (NVCT): Here's What You Should Know - MSN

Nov 11, 2024
pulisher
Nov 08, 2024

Nuvectis Pharma's VP Michael Carson sells $22.5k in stock - Investing.com

Nov 08, 2024
pulisher
Nov 08, 2024

Nuvectis Pharma's VP Michael Carson sells $22.5k in stock By Investing.com - Investing.com UK

Nov 08, 2024
pulisher
Nov 08, 2024

FY2024 EPS Estimates for Nuvectis Pharma Raised by Analyst - Defense World

Nov 08, 2024
pulisher
Nov 07, 2024

FY2024 EPS Estimate for Nuvectis Pharma Increased by Analyst - MarketBeat

Nov 07, 2024
pulisher
Nov 07, 2024

Analysts Offer Predictions for Nuvectis Pharma Q1 Earnings - Defense World

Nov 07, 2024
pulisher
Nov 06, 2024

Roth Capital Comments on Nuvectis Pharma Q1 Earnings - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Nuvectis Pharma Reports Improved Q3 Financials and Clinical Progress - TipRanks

Nov 05, 2024
pulisher
Nov 05, 2024

Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights - GlobeNewswire

Nov 05, 2024
pulisher
Nov 03, 2024

Trend Tracker for (NVCT) - Stock Traders Daily

Nov 03, 2024
pulisher
Oct 28, 2024

Nuvectis Pharma's NXP900 Shows Promise in NSCLC Treatment, NXP800 Data Update Anticipated - Vancity Buzz

Oct 28, 2024
pulisher
Oct 28, 2024

PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update - Business Wire

Oct 28, 2024
pulisher
Oct 23, 2024

NVCTNuvectis Pharma, Inc. Latest Stock News & Market Updates - StockTitan

Oct 23, 2024
pulisher
Oct 23, 2024

Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics - The Manila Times

Oct 23, 2024
pulisher
Oct 23, 2024

Nuvectis Pharma Announces Upcoming Presentations for NXP900 - GlobeNewswire

Oct 23, 2024
pulisher
Oct 20, 2024

Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - Simply Wall St

Oct 20, 2024
pulisher
Oct 13, 2024

Marshall Wace LLP Has $214,000 Stock Holdings in Nuvectis Pharma, Inc. (NASDAQ:NVCT) - Defense World

Oct 13, 2024
pulisher
Oct 07, 2024

Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference - The Manila Times

Oct 07, 2024
pulisher
Oct 02, 2024

Learn to Evaluate (NVCT) using the Charts - Stock Traders Daily

Oct 02, 2024
pulisher
Sep 24, 2024

Here's Why We're Watching Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation - Yahoo Finance

Sep 24, 2024
pulisher
Sep 21, 2024

(NVCT) Trading Advice - Stock Traders Daily

Sep 21, 2024
pulisher
Sep 19, 2024

Industry Update: 3 Exciting Precision Oncology Players to Watch - openPR

Sep 19, 2024

Nuvectis Pharma Inc Stock (NVCT) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
Cap:     |  Volume (24h):